M. F. Elias, A. Beiser, P. A. Wolf, R. Au, R. F. White and R. B. D’Agostino, “The Preclinical Phase of Alzheimer Disease; A 22-Year Prospective Study of the Framingham Cohort,” Archives of Neurology, Vol. 57, No. 6, June 2000, pp. 808-813.

has been cited by the following article:

• TITLE: Effects of Ginkgo Biloba Special Extract EGb 761® in Very Mild Cognitive Impairment (vMCI)

  AUTHORS: Brigitte Grass-Kapanke, Arija Busmane, Andris Lasmanis, Robert Hoerr, Reiner Kaschel

  KEYWORDS: Ginkgo Biloba, EGb 761®, Mild Cognitive Impairment, Memory, Concentration, Randomised Controlled Trial

  JOURNAL NAME: Neuroscience and Medicine, Vol.2 No.1, March 17, 2011

  ABSTRACT: Objective: To assess effects of EGb 761® on cognition and quality of life in subjects with very mild cognitive impair-ment. Methods: We randomized 300 subjects aged 45 to 65 with cognitive complaints and low functioning (more than one standard deviation below appropriate norm) in at least one cognitive test to double-blind treatment with once daily 240 mg EGb 761® or placebo for 12 weeks. Results: The exploratory intention-to-treat analysis showed significant im-provement (p